Citations

Clear

3042 citation(s) found for "Kumar, S".

Thrombopoietin promotes NHEJ DNA repair in hematopoietic stem cells through specific activation of Erk and NF-κB pathways and their target, IEX-1
Laval, Bérengère de , Pawlikowska, Patrycja , Barbieri, Daniela , Besnard‐Guérin, Corinne , Cico, Alba, Kumar, Rajiv , Gaudry, Muriel , Baud, Véronique , Porteu, Françoise , Kumar, Rajiv

Mayo Clinic

Blood | November 2, 2013 | Volume: 123 | Issue: 4 | Pages: 509-519

10.1182/blood-2013-07-515874 | PMID 24184684 Get It

Key Points TPO specifically activates Erk and NF-κB pathways in hematopoietic stem and progenitor cells. Erk and NF-κB cooperate to trigger their common target, Iex-1, and DNA-PK-dependent NHEJ activation in HSPCs upon irradiation.
Chronic Eosinophilic Leukemia—Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma
Rong, He , Pardanani, Animesh , Smeltzer, Jacob P., Hanson, Curtis A. , Gonsalves, Wilson I. , Gupta, Vinay Kumar , Witzig, Thomas E.

Mayo Clinic

Case Reports in Hematology | October 24, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-4

10.1155/2013/458303 | PMID 24224106 Get It

Clonal eosinophilic disorders are rare among hematological malignancies. Most eosinophilia tends to be due to secondary causes such as infections, hypersensitivity conditions, drug reactions, and connective tissue disorders. The presence of a primary clonal eosinophilic disorder such as chronic eosinophilic leukemia—not otherwise specified (NOS) in the presence of a synchronous large cell lymphoma—is rare making the diagnosis challenging. We present a case of a 51-year-old female with the aforementioned presentation and demonstrate the extensive workup performed to identify the diagnosis.
Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis
Kourelis, Taxiarchis , Kumar, Shaji , Lacy, Martha Q. , Hayman, Suzanne R. , Zeldenrust, Steven R., Leung, Nelson , Kyle, Robert A. , Russell, Stephen J. , Dingli, David , Lust, John A., Lin, Yi , Kapoor, Prashant , McCurdy, Arleigh , Dispenzieri, Angela , Kourelis, Taxiarchis V, Gertz, Morie A. , Buadi, Francis K. , Rajkumar, S. Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi , McCurdy, Arleigh

Mayo Clinic

Journal of Clinical Oncology | October 22, 2013 | Volume: 31 | Issue: 34 | Pages: 4319-4324

10.1200/jco.2013.50.8499 | PMID 24145344 Get It

Purpose There is consensus that patients with light chain (AL) amyloidosis with hypercalcemia, renal failure, anemia, and lytic bone lesions attributable to clonal expansion of plasma cells (CRAB criteria) also have multiple myeloma (MM). The aim of this study was to examine the spectrum of immunoglobulin AL amyloidosis with and without MM, with a goal of defining the optimal bone marrow plasma cell (BMPC) number to qualify as AL amyloidosis with MM. Patients and Methods We identified 1,255 patients with AL amyloidosis seen within 90 days of diagnosis between January 1, 2000, and December 31, 2010. We defined a population of patients with coexisting MM on the basis of the existence of CRAB criteria (AL-CRAB). Receiver operating characteristic analysis determined the optimal BMPC cut point to predict for 1-year mortality in patients with AL amyloidosis without CRAB to produce two additional groups: AL only (≤ 10% BMPCs) and AL plasma cell MM (AL-PCMM; > 10% BMPCs). Results Among the 1,255 patients, 100 (8%) had AL-CRAB, 476 (38%) had AL-PCMM, and 679 (54%) had AL only. Their respective median overall survival rates were 10.6, 16.2, and 46 months (P < .001). Because the outcomes of AL-CRAB and AL-PCMM were similar, they were pooled for univariate and multivariate analyses. On multivariate analysis, pooled AL-CRAB and AL-PCMM retained negative prognostic value independent of age, Mayo Clinic AL amyloidosis stage, prior autologous stem-cell transplantation, and difference between the involved and uninvolved free light chain. Conclusion Patients with AL amyloidosis who have more than 10% BMPCs have a poor prognosis, similar to that of patients with AL-CRAB, and should therefore be considered together as AL amyloidosis with MM.
Smoldering multiple myeloma requiring treatment: time for a new definition?
Dispenzieri, Angela , Stewart, A. Keith, Chanan‐Khan, Asher , Rajkumar, S. Vincent , Kyle, Robert A. , Fonseca, Rafaël , Kapoor, Prashant , Bergsagel, P. Leif , McCurdy, Arleigh , Lacy, Martha Q. , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Reeder, Craig B. , Dingli, David , Hayman, Suzanne R. , Leung, Nelson , Lin, Yi , Kumar, Shaji , Bergsagel, P. Leif , Gertz, Morie A. , Roy, Vivek , Buadi, Francis K. , Mıkhael, Joseph , Rajkumar, S Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi , Fonseca, Rafael , McCurdy, Arleigh

Mayo Clinic

Blood | October 21, 2013 | Volume: 122 | Issue: 26 | Pages: 4172-4181

10.1182/blood-2013-08-520890 | PMID 24144641 Get It

Abstract Smoldering multiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premalignant disorder) and active multiple myeloma (MM). Until recently, no interventional study in patients with SMM showed improved overall survival (OS) with therapy as compared with observation. A report from the PETHEMA-GEM (Programa Español de Tratamientos en Hematologica) group described both fewer myeloma-related events and better OS among patients with high-risk SMM who were treated with lenalidomide and dexamethasone. This unique study prompted us to review current knowledge about SMM and address the following questions: (1) Are there patients currently defined as SMM who should be treated routinely? (2) Should the definitions of SMM and MM be reconsidered? (3) Has the time come when not treating is more dangerous than treating? (4) Could unintended medical harm result from overzealous intervention? Our conclusion is that those patients with the highest-risk SMM (extreme bone marrow plasmacytosis, extremely abnormal serum immunoglobulin free light chain ratio, and multiple bone lesions detected only by modern imaging) should be reclassified as active MM so that they can receive MM-appropriate therapy and the paradigm of careful observation for patients with SMM can be preserved.
Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder
Flanagan, Eoin P. , Aksamit, Allen J. , Kumar, Neeraj , Morparia, Neha, Morparia, Neha P, Weinshenker, Brian G. , Keegan, B. Mark , Flanagan, E P

Mayo Clinic

Neurology Clinical Practice | October 14, 2013 | Volume: 3 | Issue: 5 | Pages: 448-451

10.1212/cpj.0b013e3182a78f82 | PMID 29473607 Get It

Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease
Kosaraju, Jayasankar , Murthy, Vishakantha , Khatwal, Rizwan Basha, Dubala, Anil, Chinni, Santhivardhan , Nataraj, Satish Kumar Muthureddy, Basavan, Duraiswamy

Mayo Clinic

Journal of Pharmacy and Pharmacology | October 12, 2013 | Volume: 65 | Issue: 12 | Pages: 1773-1784

10.1111/jphp.12148 | PMID 24117480 Get It

Abstract Objectives Adults who develop type 2 diabetes (T2D) at later stages are at a higher risk of developing Alzheimer's disease (AD). Pharmacological agents such as dipeptidyl peptidase-4 (DPP-4) inhibitors that increase the levels of glucagon-like peptide-1 (GLP-1) and ameliorate T2D have also become promising candidates as disease-modifying agents in the treatment of AD. The present study investigates the efficacy of vildagliptin, a DPP-4 inhibitor in a streptozotocin (STZ)-induced rat model of AD. Methods Three months following the induction of AD by intracerebral injection of STZ, animals were orally administered with vildagliptin (2.5, 5 and 10 mg/kg) for 30 days. Dose-dependent and time-course effects of vildagliptin on memory retention were investigated during the course of treatment. Following treatment, the animals were sacrificed, and brain tissues were used to evaluate the effects of vildagliptin on hippocampal and cortical GLP-1 levels, amyloid beta (Aβ) burden, tau phosphorylation and inflammatory markers. Key findings The results reveal a time-dependent improvement in memory retention and a dose-dependent attenuation of Aβ, tau phosphorylation and inflammatory markers and increased GLP-1 levels. Conclusions These robust therapeutic effects of vildagliptin demonstrate a unique mechanism for Aβ and tau clearance and reverse the cognitive deficits and pathology observed in AD.
Akt inhibitor MK2206 selectively targets CLL B‐cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis
Lesnick, Connie , Erlichman, Charles , Leis, José F., Secreto, Charla, Sassoon, Traci, Call, Timothy G. , Bowen, Deborah A., Conte, Michael, Kumar, Shaji , Ding, Wei , Shanafelt, Tait D. , Kay, Neil E.

Mayo Clinic

British Journal of Haematology | October 11, 2013 | Volume: 164 | Issue: 1 | Pages: 146-150

10.1111/bjh.12564 | PMID 24111951 Get It

IC‐P‐089: FDG‐PET and PiB‐PET imaging in asymptomatic at‐risk carriers of a novel octapeptide repeat insertion in PRNP
Lowe, Val J. , Przybelski, Scott A. , Weigand, Stephen D. , Spychalla, Anthony J., Jones, David, Kumar, Neeraj , Rademakers, Rosa , Petersen, Ronald, Parisi, Joseph E. , Boeve, Bradley F. , Kantarci, Kejal , Vemuri, Prashanthi , McDade, Eric , Baker, Matthew , Knopman, David S. , Petersen, Ronald, Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2013.05.086 Get It

P3–093: FDG‐PET and PiB‐PET imaging in asymptomatic at‐risk carriers of a novel octapeptide repeat insertion in PRNP
Lowe, Val J. , Przybelski, Scott A. , Weigand, Stephen D. , Spychalla, Anthony J., Jones, David, Kumar, Neeraj , Rademakers, Rosa , Petersen, Ronald, Parisi, Joseph, Boeve, Bradley F. , Kantarci, Kejal , Vemuri, Prashanthi , Jones, David, McDade, Eric , Baker, Matthew , Knopman, David S. , Petersen, Ronald, Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2013.05.1163 Get It

Treatment trade‐offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies
Burnette, Brian L., Dispenzieri, Angela , Kumar, Shaji , Harris, Ann M. , Sloan, Jeff A. , Tilburt, Jon C. , Kyle, Robert A. , Rajkumar, S. Vincent , Rajkumar, S Vincent , Dispenzieri, Angela

Mayo Clinic

Cancer | October 8, 2013 | Volume: 119 | Issue: 24 | Pages: 4308-4315

10.1002/cncr.28340 | PMID 24105720 Get It

BACKGROUNDTwo randomized trials have demonstrated improved progression‐free survival (PFS) with lenalidomide maintenance after autologous transplantation for multiple myeloma (MM). Overall survival (OS) results are conflicting, and quality‐of‐life (QOL) data are lacking. The authors conducted a systematic survey of patients with MM regarding what constitutes a meaningful benefit that would make burdens of maintenance treatments (toxicity and cost) acceptable.METHODSA self‐administered survey was mailed to 1159 consecutive, living patients who were evaluated at Mayo Clinic. The survey provided background information on the standard of care for MM and data on maintenance. Patients were asked to estimate the magnitude of OS benefit that would be acceptable for various degrees of toxicity and cost.RESULTSOf 1159 surveys sent, 886 patients (83.2%) responded, and 736 patients returned a completed survey (66% raw response rate). The most worrisome potential toxicity was identified as peripheral neuropathy by 27% of patients, cytopenias by 24%, deep vein thrombosis by 20%, fatigue by 15%, nausea by 8%, and diarrhea/constipation by 7%. If treatment was free, had no toxicity, and the OS benefit was ≤1 year, then 49% of patients indicated that they would choose maintenance; with moderate toxicity, this proportion decreased to 42%. Adding a treatment cost of $25 per month decreased the proportion that would choose maintenance to 39% of patients.CONCLUSIONSThe current results indicated that willingness to receive maintenance treatment declined when actual benefits were provided in concrete numeric terms compared with a general statement of PFS benefit. The authors also observed that the magnitude of benefit required to consider maintenance was affected by cost and toxicity. Cancer 2013;119:4308–4315. © 2013 American Cancer Society.